• 1
    Atkins C, Bonagura J, Ettinger S, et al. Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med 2009;23:11421150.
  • 2
    Ettinger SJ, Benitz AM, Ericsson GF, et al. Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. J Am Vet Med Assoc 1998;213:15731577.
  • 3
    The BENCH Study Group. The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: Results of a multicenter, prospective, randomized, double-blinded, placebo-controlled, long-term clinical trial. J Vet Cardiol 1999;1:718.
  • 4
    Häggström J, Boswood A, O'Grady M, et al. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: The QUEST Study. J Vet Intern Med 2008;22:11241135.
  • 5
    Lombard C, Jöns O, Bussadori C. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs. J Am Anim Hosp Assoc 2006;42:249261.
  • 6
    Wolley R, Smith P, Munro E, et al. Effect of treatment type on vertebral heart size in dogs with myxomatous mitral valve disease. Int J Appl Res Vet Med 2007;5:4348.
  • 7
    Lord P, Eriksson A, Häggström J, et al. Increased pulmonary transit times in asymptomatic dogs with mitral regurgitation. J Vet Intern Med 2003;17:824829.
  • 8
    Kuikka J, Timisjarvi J, Tuominen M. Quantitative radiocardiographic evaluation of cardiac dynamics in man at rest and during exercise. Scan J Clin Lab Invest 1979;39:423434.
  • 9
    Eriksson A, Hansson K, Häggström J, et al. Pulmonary blood volume in mitral regurgitation in Cavalier King Charles Spaniels. J Vet Intern Med 2010;24:13931399.
  • 10
    Häggström J, Hansson K, Karlberg B, et al. Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation. Am J Vet Res 1996;57:6451652.
  • 11
    Hansson K, Häggström J, Kvart C, et al. Left atrial to aortic root root indices using two-dimensional and M-mode echocardiography in dogs with and without left atrial enlargement. Vet Radiol Ultrasound 2002;43:568757.
  • 12
    Cornell C, Kittleson M, Della Torre P, et al. Allometric scaling of M-mode cardiac measurements in normal adult dogs. J Vet Intern Med 2004;18:311321.
  • 13
    Buchanan J, Bucheler J. Vertebral scale system to measure canine heart size in radiographs. J Am Vet Med Assoc 1995;206:194199.
  • 14
    Tilley L. Essentials of Canine and Feline Electrocardiography, 2nd ed. Philadelphia, PA: Lea & Febinger; 1985:134.
  • 15
    Tidholm A, Häggström J, Hansson K. Effects of dilated cardiomyopathy on the renin-angiotensin-aldosterone system, atrial natriuretic peptide activity, and thyroid hormone concentrations in dogs. Am J Vet Res 2001;62:961967.
  • 16
    Tidholm A, Häggström J, Hansson K. Vasopressin, cortisol, and catecholamine concentrations in dogs with dilated cardiomyopathy. Am J Vet Res 2005;66:17091717.
  • 17
    Tarnow I, Olsen LH, Kvart C, et al. Predictive value of natriuretic peptides in dogs with mitral valve disease. Vet J 2009;180:195201.
  • 18
    Ohte N, Cheng CP, Suzuki M, et al. The cardiac effects of pimobendan (but not amrinone) are preserved at rest and during exercise in conscious dogs with pacing-induced heart failure. J Pharmacol Exp Ther 1997;282:2331.
  • 19
    Pagel PS, Hettrick DA, Warltier DC. Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs. Br J Pharmacol 1996;119:609615.
  • 20
    The IMPROVE Study Group. Acute and short-term hemodynamic, echocardiographic, and clinical effects of enalapril maleate in dogs with naturally acquired heart failure: Results of the Invasive Multicenter PROspective Veterinary Evaluation of enalapril study. J Vet Intern Med 1995;9:234242.
  • 21
    Suzuki S, Ishikawa T, Hamabe L, et al. The effect of furosemide on left atrial pressure in dogs with mitral valve regurgitation. J Vet Intern Med 2011;25:244250.
  • 22
    Hori Y, Sano N, Kanai K, et al. Acute cardiac volume load-related changes in plasma atrial natriuretic peptide and N-terminal pro-B-type natriuretic peptide concentrations in healthy dogs. Vet J 2010;185:317321.
  • 23
    Levine RA, Nattel S. Looking into the left atrial crystal ball: A ray of hope for patients with organic mitral regurgitation. J Am Coll Cardiol 2010;56:579581.
  • 24
    Kanno N, Kuse H, Kawasaki M, et al. Effects of pimobendan for mitral valve regurgitation in dogs. J Vet Med Sci 2007;69:373377.
  • 25
    Suzuki S, Fukushima R, Ishikawa T, et al. The effect of pimobendan on left atrial pressure in dogs with mitral valve regurgitation. J Vet Intern Med 2011;25:13281333.
  • 26
    Fox PR. Pathology of myxomatous mitral valve disease in the dog. J Vet Cardiol 2012;14:103126.
  • 27
    Kittleson MD, Eyster GE, Knowlen GG, et al. Myocardial function in small dogs with chronic mitral regurgitation and severe congestive heart failure. J Am Vet Med Assoc 1984;184:455459.
  • 28
    Borgarelli M, Tarducci A, Zanatta R, et al. Decreased systolic function and inadequate hypertrophy in large and small breed dogs with chronic mitral valve insufficiency. J Vet Intern Med 2007;21:6167.
  • 29
    Sweet CS, Ludden CT, Frederick CM, et al. Comparative hemodynamic effects of MK-422, a converting enzyme inhibitor, and a renin inhibitor in dogs with acute left ventricular failure. J Cardiovasc Pharmacol 1984;6:10671075.
  • 30
    Dillon AR, Dell'Italia LJ, Tillson M, et al. Left ventricular remodeling in preclinical experimental mitral regurgitation of dogs. J Vet Cardiol 2012;14:7392.
  • 31
    Suga H. Cardiac energetics: From E(max) to pressure-volume area. Clin Exp Pharmacol Physiol 2003;30:580585.
  • 32
    Gaasch WH, Meyer TE. Left ventricular response to mitral regurgitation: Implications for management. Circulation 2008;118:22982303.
  • 33
    Gardner SY, Atkins CE, Rausch WP, et al. Estimation of 24-h aldosterone secretion in the dog using the urine aldosterone:creatinine ratio. J Vet Cardiol 2007;9:17.
  • 34
    Häggström J, Hansson K, Kvart C, et al. Effects of naturally acquired decompensated mitral valve regurgitation on the renin-angiotensin-aldosterone system and atrial natriuretic peptide concentration in dogs. Am J Vet Res 1997;58:7782.
  • 35
    Lantis AC, Atkins CE, DeFrancesco TC, et al. Effects of furosemide and the combination of furosemide and the labeled dosage of pimobendan on the circulating renin-angiotensin-aldosterone system in clinically normal dogs. Am J Vet Res 2011;72:16461651.
  • 36
    Sayer MB, Atkins CE, Fujii Y, et al. Acute effect of pimobendan and furosemide on the circulating renin-angiotensin-aldosterone system in healthy dogs. J Vet Intern Med 2009;23:10031006.
  • 37
    Mochel JP, Peyrou M, Fink M, et al. Capturing the dynamics of systemic renin-angiotensin-aldosterone system (RAAS) peptides heightens the understanding of the effect of benazepril in dogs. J Vet Pharmacol Therap 2013;36:174180.
  • 38
    Cowley AW Jr. Vasopressin and blood pressure regulation. Clin Physiol Biochem 1988;6:150162.
  • 39
    Cody RJ. The sympathetic nervous system and the renin-angiotensin-aldosterone system in cardiovascular disease. Am J Cardiol 1997;80:9J14J.
  • 40
    Luchner A, Borgeson DD, Grantham JA, et al. Relationship between left ventricular wall stress and ANP gene expression during the evolution of rapid ventricular pacing-induced heart failure in the dog. Eur J Heart Fail 2000;2:379386.
  • 41
    Luchner A, Stevens TL, Borgeson DD, et al. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol 1998;274:H1684H1689.
  • 42
    Canaff L, Brechler V, Reudelhuber TL, et al. Secretory granule targeting of atrial natriuretic peptide correlates with its calcium-mediated aggregation. Proc Natl Acad Sci USA 1996;93:94839487.
  • 43
    Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90:195203.
  • 44
    Hezzell MJ, Boswood A, Chang YM, et al. The combined prognostic potential of serum high-sensitivity cardiac troponin I and N-terminal pro-B-type natriuretic peptide concentrations in dogs with degenerative mitral valve disease. J Vet Intern Med 2012;26:302311.
  • 45
    Wolf J, Gerlach N, Weber K, et al. Lowered N-terminal pro-B-type natriuretic peptide levels in response to treatment predict survival in dogs with symptomatic mitral valve disease. J Vet Cardiol 2012;14:399408.
  • 46
    Bilder GE, Siegl PKS, Schofield TL, et al. Chronotropic stimulation: A primary effector for release of atrial natriuretic factor. Cirk Res 1989;64:799805.